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Background: Sleep deprivation is common in critically ill patients in intensive care units (ICU). It can result in
delirium, difficulty weaning, repeated nosocomial infections, prolonged ICU length of stay and increased ICU
mortality. Melatonin, a physiological sleep regulator, is well known to benefit sleep quality in certain people, but
evidence for the effectiveness in ICU sleep disturbance is limited.
Methods/Design: This study has a prospective, randomized, double-blind, controlled, parallel-group design. Eligible
patients are randomly assigned to one of the two treatment study groups, labelled the ‘melatonin group’ or the
‘placebo group’. A dose of 3 mg of oral melatonin or placebo is administered at 9:00 pm on four consecutive days.
Earplugs and eye masks are made available to every participant. We plan to enrol 198 patients. The primary
outcome is the objective sleep quality measured by the 24-hour polysomnography. The secondary outcomes are the
subjective sleep quality assessed by the Richards Campbell Sleep Questionnaire, the anxiety level evaluated by the
Visual Analogue Scale-Anxiety, the number of delirium-free days in 8 and 28 days, the number of ventilation-free days
in 28 days, the number of antibiotic-free days, ICU length of stay, the overall ICU mortality in 28 days and the incidence
and severity of the side effects of melatonin in ICU patients. Additionally, the body stress levels, oxidative stress levels
and inflammation levels are obtained via measuring the plasma melatonin, cortisone, norepinephrine, malonaldehyde
(MDA), superoxide dismutase(SOD), interleukin-6 (IL-6) and interleukin-8 (IL-8)concentrations.
Discussion: The proposed study will be the first randomized controlled study to use the polysomnography, which is
the gold standard of assessing sleep quality, to evaluate the effect of melatonin on the sleep quality and circadian
rhythms of ICU patients. The results may recommend a new treatment for ICU patients with sleep deprivation that is
safe, effective and easily implementable in daily practice.
Trial registration: This study was registered with ClinicalTrials (NCT; registration number: ChiCTR-TRC-14004319) on
4 March 2013.
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Sleep deprivation is a major concern in critically ill pa-
tients in intensive care units (ICU). Several studies have
shown that poor sleep quality and the inability to sleep
are the second largest stressors and rank among the top
three major sources of anxiety during ICU stays [1-3].* Correspondence: xxm_fxyy@sina.cn
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unless otherwise stated.Sleep for ICU patients is characterised by frequent dis-
ruptions, loss of circadian rhythms and a paucity of time
spent in restorative sleep stages. Typical findings de-
scribed by polysomnography (PSG), the gold standard of
assessing sleep quality, include increased latency, a
higher proportion of non-rapid eye movement (NREM)
sleep stage 1 and 2 (or light sleep), and reduced restora-
tive slow wave (SW) and rapid eye movement (REM)
sleep, largely because of frequent waking. Although ICU
patients may experience normal or near normal total
sleep time (TST), approximately 50% of this sleep occursLtd. This is an Open Access article distributed under the terms of the Creative
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by Elliot et al. a 24-hour PSG was used to evaluate the
sleep quality in ICU patients [5]. They found that despite
improvements in ICU design, technology and healthcare
personnel training, there has been no improvement in
the ICU sleep problem [5-7]. It has been found that
there are many extrinsic and intrinsic factors of sleep
deprivation in the ICU setting including noise, light,
nursing procedures, the presence of existing diseases, in-
flammatory mediators, anxiety, pain, sedative and opioid
medications and mechanical ventilator setting [8-12].
Furthermore, the occurrence of ICU sleep deprivation is
associated with detrimental outcomes, including deli-
rium, difficulty weaning, increased nosocomial infec-
tions, prolonged ICU length of stay (LOS) and increased
ICU mortality [13].
Conversely, despite the poor sleep quality that disturbs
almost all ICU patients, clinicians remain reluctant to
administer traditional sedative-hypnotic drugs in pa-
tients with sleep disorders. The major concerns are the
side effects of these drugs, mainly that they destroy the
structure of sleep, reduce the clinician’s ability to moni-
tor the level of consciousness, induce respiratory depres-
sion and lower blood pressure [14].
Sleep goals for ICU patients are to get enough sleep,
reset the disordered circadian rhythms, adjust the abnor-
mal sleep structure, reduce sleep interruption, overcome
fatigue and anxiety, facilitate nursing care and treat dis-
ease. An ideal therapy for improving sleep in the ICU
should be economical, feasible, rapid in onset and offset
and without local and systemic adverse effects. At pre-
sent, there is no effective treatment in use to improve
ICU sleep that covers all of these ideal properties.
Current studies are mainly focused on non-drug treat-
ments such as earplugs and/or eye masks [10,15] and
imagery and relaxation [16]. These treatments are rela-
tively safe but do not guarantee efficacy. Among the
studies, the clinical research on earplugs and/or eye
masks has some maturity [15]. Some domestic and inter-
national experts and scholars have recommended that
ICUs incorporate earplugs and/or eye masks into routine
nursing care [17]. However, Bourne et al. [18] and Gabor
et al. [7] showed that environmental factors were re-
sponsible for a fraction of arousals and awakenings, and
Perras et al. [19] indicated that the physiological regula-
tion of melatonin secretion by darkness and light was
abolished in severely ill patients in the ICU. Therefore,
treatments based on environmental factors might have
limited effects. Recently melatonin, a physiological sleep
aid, has gained interest among ICU scholars.
Melatonin (N-acetyl-methoxytryptamine) is a neurohor-
mone mainly secreted by the pineal gland. Light signals
play the most important role in the synthesis and secre-
tion of melatonin in organisms. Thus, the environmentalcues that regulate an organism’s biological clock are
predominantly the daily alternation of light and darkness
acting via the retina and retina-hypothalamic pathways
directly on the suprachiasmatic nuclei (SCN). Melatonin
secretion increases directly with the length of darkness.
Increased light intensity decreases the quantity of endo-
genous melatonin produced and shifts the pattern of
release throughout the circadian clock. Endogenous mela-
tonin is released at night, beginning at approximately
9:00 pm with a peak release at between 2:00 and 4:00.
Melatonin release is typically inhibited between 7:00 and
9:00, coinciding with the peak of endogenous cortisol [20].
This secretion pattern makes the physiological activities in
the human body, such as the sleep-wake cycle, syn-
chronised with the circadian rhythm. Thus, melatonin is a
good sleep aid. In addition, current in vitro and in vivo ex-
periments suggest that melatonin might act as a mood
stabilizer, relieve stress, act as an anti-oxidation and anti-
inflammation agent, suppress pathogens and protect the
functioning of multiple organs [20], which are undoub-
tedly helpful to the recovery of ICU patients, and thereby
might improve sleep.
Prolonged-release melatonin (Circadin), an oral medi-
cation to regulate physiological sleep and the circadian
rhythm designed to mimic the endogenous pattern of
melatonin production, is licensed for the treatment of
primary insomnia in patients aged 55 years and over. It
results in significant and clinically meaningful improve-
ments in sleep quality, morning alertness, sleep onset la-
tency and quality of life, without withdrawal symptoms
upon discontinuation [21]. Recently, extensive clinical
trials also noted that melatonin could be beneficial in
different populations with sleep disorders. Firstly, me-
latonin might be effective for insomnia and daytime
sleepiness caused by time zone changes [22] and work
shifts [23] that induce the malfunctioning of biological
clocks. This is because melatonin may maintain the syn-
chronisation in situations where the circadian rhythms
are jeopardized and resynchronize after a period of free-
run release. Secondly, melatonin might improve the
sleep quality of non-ICU critically ill patients with dialy-
sis [24], moderate to severe COPD [25] and asthma [26].
In addition, the available clinical data shows that peri-
operative use of melatonin is effective in reducing pre-
operative anxiety [27] and plays a role in the prevention
of postoperative delirium [28], as well as possessing cer-
tain analgesic qualities, and may reduce concomitant
opioid use in the postoperative period with a corre-
sponding reduction in opioid-associated side effects [29].
Melatonin has been given safely to humans in doses of 1
to 15 mg. Although treatment results in plasma levels up
to 100 times the normal peak night concentration ap-
proximately 1 hour after ingestion, it has a wide safety
margin [30]. In a meta-analysis, Buscemi et al. concluded
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that the most common side effects of melatonin use were
headache, dizziness, nausea and drowsiness [31]. Most
importantly, although melatonin has hypnotic, sedative
and analgesic properties, it has few respiratory and he-
modynamic effects.
The interest in melatonin as a potential therapeutic or
prophylactic agent in the management of sleep dis-
turbance in the ICU derives from the demonstrated low
plasma concentrations and altered secretion patterns of
melatonin in critically ill patients. Shilo et al. studied the
day secretions of melatonin in a group of ICU patients
compared to a group of patients in ordinary medical
wards. They found that the nocturnal peak of melatonin
was missing in most ICU patients [32]. Mundigler et al.
described a disturbed pattern of circadian secretion of
melatonin in ICU patients with sepsis (16 out of 17 pa-
tients) but a preserved circadian rhythm in ICU patients
who did not have sepsis (six out of seven patients) [33].
Olofsson et al. found that the circadian rhythm of mela-
tonin secretion was abolished in mechanically ventilated
patients in the ICU [34]. Perras et al. suggested that the
nocturnal melatonin concentrations in ICU patients were
negatively correlated with illness severity [19]. In addition,
various drugs commonly used in the ICU have been re-
ported to alter melatonin secretion and to decrease the
plasma levels of melatonin [35] including benzodiaze-
pines, non-steroidal anti-inflammatory drugs (NSAIDs),
corticosteroids and beta-blockers. Therefore, low mela-
tonin levels, poor sleep quality and illness have a reci-
procal causation interaction and form a vicious circle. The
supplementation of exogenous melatonin to remodel the
melatonin level in the human body that approaches
the physiological state might be one of most effective
strategies for improving sleep.
Both melatonin and cortisol are biological markers of
the circadian rhythm. Some previous studies have shown
that there is a hypo-secretion of melatonin and an over-
all high cortisol excretion in most patients in the ICU.
Cortisol is an important stress hormone that would be
invoked by the noise, light and other stressors in the
ICU and leads to anxiety and sleep disturbance. It is
known that melatonin can reduce the adrenocortical re-
sponse to stress and down-regulate the synthesis and
release of cortisol. Moreover, in addition to reducing the
stress, the role of melatonin as an antioxidant and anti-
inflammatory agent or part of sepsis treatment is widely
discussed. Thus, administration of melatonin might sig-
nificantly benefit ICU patients.
Recently, Mistraletti et al. studied the pharmacoki-
netics of melatonin given orally to ICU patients and
found a good oral bioavailability of the drug [36]. Ad-
ditionally, several studies suggest it can take up to three
days to achieve the desired effect of melatonin on sleepquality [13,18,30,37]. Until now, there have been only
three studies investigating the influence of melatonin
treatment on sleep quality in critically ill patients. Shilo
et al. [37] and Bourne et al. [18] found that melatonin
improved sleep quality and sleep length in critically ill
patients in the ICU, however Ibrahim et al. [30] found a
negative result in their study. There are some inconsis-
tencies regarding the inclusion criteria, the drug in-
cluded, the sound and light control and the monitoring
method in these three studies, specifically as follows:(1)
Ibrahim et al.’s study included patients who had unli-
mited use of sedatives and analgesics that might affect
serum melatonin levels; (2) there was no uniformity for
the control of patient exposure to noise and light among
the three studies, which may have a more powerful ef-
fect on observed sleep than even the pharmacological
levels of melatonin achieved; and, most significantly, (3)
they did not use the PSG (the gold standard for asses-
sing sleep) to evaluate sleep quality and ignored the im-
portance of monitoring the all-day sleep, likely because
it is very difficult to perform 24-hour PSG in severely ill
patients in the ICU.
The aim of the present work is to evaluate the efficacy
and safety of melatonin for ICU sleep deprivation. Our
hypothesis is that melatonin will improve the sleep qua-
lity in ICU patients. The present article proposes a
protocol for a clinical study consisting of a double-blind,
randomized, placebo-controlled trial with melatonin in
adult critically ill patients with ICU sleep deprivation. The
present report will follow the guidelines expressed by the
Consolidated Standards of Reporting Trials (CONSORT).
Methods/Design
Study design and outcomes
The present study is a prospective, single-centre, ran-
domized, double-blind, placebo-controlled, two-arm trial
in patients with sleep deprivation in the ICU. All eligible
patients in the ICU will be 1:1 randomized to the treat-
ment intervention with melatonin or placebo. The ob-
jective of the trial is to evaluate the efficacy and safety of
melatonin for ICU sleep deprivation. The definitions of
the variables in the objectives are reported in Table 1.
The primary outcome will be to determine the effect
of melatonin administration on the 24-hour sleep-wake
cycle and subjective sleep quality, including night/day
sleep time, total sleep time(TST), percentages of NREM
stage 1/2, slow wave sleep(SWS) and REM, the incidence
of arousals per hour, the duration of sleep without wa-
king and the number of sleep periods.
The secondary outcomes will be: (a) objective sleep
quality as assessed by the Richards Campbell Sleep
Questionnaire (RCSQ); (b) anxiety levels measured using
the Visual Analogue Scale-Anxiety (VAS-A); (c) stress
levels via measuring the plasma melatonin, cortisone
Table 1 Definition of study objectives
Objective Definition
Objective sleep quality Total sleep time, the length of sleep at night (9:00 pm - 7:00 am) and during the day (7:00 am - 9:00 pm),
sleep architecture (NREM stage 1 and 2, SWS, REM), and sleep disruption (the number of arousals and
duration of sleep), which will be monitored for one 24-hour period using a portable PSG device.
Subjective sleep quality The subjective feelings of nightly sleep status of the patient, including sleep depth, wake time after sleep
onset, number of awakenings after sleep onset, latency to sleep onset, and sleep quality. It will be
evaluated using the RCSQ [38,39].
Anxiety level ICU anxiety is defined as a state marked by apprehension, agitation, increased motor activity, number of
arousals, and fearful withdrawal during the ICU stay [40]. It will be assessed using the VAS-A.
Delirium-free days in 8 and 28 days Number of days that the patient is not delirious over 8 and 28 days starting from the day of inclusion.
Patients are diagnosed as delirious when they have at least one positive CAM-ICU screening during their
ICU stay. A delirium-free day is defined as a negative CAM-ICU screening during that day. In case a delirious
patient is discharged from the ICU, a delirium-free day is defined as a delirium observation scale score of
less than 3 during a complete day [41].
Ventilator-free days in 28 days Time in days that the patient is not on a mechanical ventilator. If the patient is ventilated mechanically,
including invasive and non-invasive ventilation several times during one ICU admission, then the non-
ventilator times are added. Ventilator-free days (in 28 days) will be calculated.
Antibiotic-free days in 8 and 28 days Number of days that the patient does not require any antibiotics at 8 and 28 days from randomization will
be calculated.
ICU length of stay Duration of admission to the ICU.
Overall ICU mortality at 28 days Survival time will be assessed. Patients will be classified as either alive at study day 28 or dead at study day
28. Differences between the two strategies in mortality rates will be evaluated using the assumption of
asymptotic normality. Estimates of relative risks and odds ratios and the corresponding 95% confidence
intervals will be presented.
Side effects Headache, dizziness, nausea, and drowsiness, determined daily by physical examination by the intensivist,
and withdrawal symptoms upon discontinuation evaluated after the drugs are stopped.
NREM, None rapid eye movement; SWS, Slow wave sleep; REM, Rapid eye movement; PSG, Polysomnography; RCSQ, Richards Campbell sleep questionnaire;
VAS-A, Visual analogue scale-anxiety; CAM-ICU, The confusion assessment method for the intensive care unit.
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levels of inflammation; (f ) the number of delirium-free
days in 8 and 28 days; (g) the number of ventilator-free
days in 28 days; (h) the number of antibiotic-free days in
8 and 28 days; (i) ICU length of stay; (j) overall ICU
mortality at 28 days; (k) the incidence and severity of
melatonin side effects in ICU patients.
Study setting and population
The study setting is the comprehensive ICU, Fuxing
Hospital, Capital Medical University, Beijing, China. All
patients admitted to our ICU with acute respiratory fai-
lure requiring mechanical ventilation and tracheotomy
to assist weaning are screened daily for study eligibility.
Inclusion criteria are: (a) age ≥18-years-old; (b) Glasgow
Coma Scale (GCS) score ≥10; (c) sedation with propo-
fol, morphine, alfentanil and dexmedetomidine has been
discontinued for a minimum of 36 hours (48 hours for
lorazepam and midazolam); (d) expected mechanical ven-
tilation days ≥5 days; (e) patients are clinically and bio-
logically stable and pass the weaning screening and are
therefore ready to be weaned from mechanical ventilation.
Exclusion criteria are: (a) pregnant or breast-feeding
women; (b) preadmission treatment of sleep disturbances;
(c) a history of convulsions, psychiatric or neurological
disease, sleep apnoea, deafness or blindness; (d) alcoholconsumption ≥50 units per week or drug use; (e) liver in-
sufficiency (child-Pugh class C); (f) renal insufficiency (re-
quires dialysis); (g) severe heart failure (the New York
Heart Association classification III/IV); (h) intestinal ob-
struction, ileus, gastroparesis or other conditions likely to
affect the enteral absorption of melatonin; (i) the use of
drugs that might alter melatonin secretion and decrease
plasma levels of melatonin, such as benzodiazepines,
NSAIDs, corticosteroids, beta-blockers, haloperidol and
amiodarone [42,43]; (j) known allergy to melatonin; (k) re-
admitted to the ICU after randomization to the study;
(l) enrolled in another trial.
Ethical aspects and informed consent
When a patient is identified as eligible for the study, im-
mediate contact will be made with the 24-hour on-call
study coordinator who will confirm eligibility. The at-
tending physician will introduce the patient and their
family to the study coordinator. The physician will make
sure the patient and family know the credentials of the
study coordinator and will explain that this person is
going to discuss the study program that is being con-
ducted and that this person is qualified to do so. Every
relevant aspect of the project will be described. The
study coordinator will stop frequently, ask if there are
any questions, and request that the family repeat back
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understanding.
The study coordinator will explain that there is a possi-
bility that the patient may suffer from poor sleep quality,
and if so, the patient’s health could decline. The coor-
dinator will say that there is a physiological sleep aid that
provides good sleep quality without respiratory depres-
sion, while facilitating the patient’s condition. Additionally,
he will explain that in a small percentage of patients,
melatonin could cause headache, dizziness, nausea and
drowsiness. The potential advantages of using or not using
melatonin will be described. The study coordinator will be
especially careful to assure the family that they are free to
decline consent without consequences and that they can
withdraw consent at any time without impact on treat-
ment. Family members will be provided with contact
information for the study coordinator, the local co-
investigator and the local ethical committee. Written con-
sent will be obtained in the presence of a witness. A
register is kept of all patients evaluated for inclusion and
of patients who withdraw from the study. The latter are
clinically followed up without their data being analysed in
the study.
The study protocol and consent forms were approved
by the Institutional Review Board of Fuxing Hospital affi-
liated with Capital Medical University (approval number
KY2014-22) and by the Chinese Clinical Trial Registry
(approval number ChiCTR-TRC-14004319). The Fuxing
Hospital’s Institutional Review Board gave positive advice
for the addition of their ICU as the study site.
Randomization with double-blind and allocation
concealment
The study has a prospective, randomized, double-blind,
placebo-controlled, parallel-group design. Eligible pa-
tients are randomly assigned to one of the two treatment
study groups, labelled the ‘melatonin group’ or the
‘placebo group’. Randomization is based on a computer-
generated random digits table and follows a concealed
process using sealed and numbered envelopes that allo-
cate the patient to either of the two arms of the study.
Patients may be randomized into this study only once,
unless they were discharged from the hospital and were
re-admitted more than 180 days after their first enrol-
ment. The study does not allow crossover, and if any
occur, they will be reported as protocol violations.
The experimental drug and a placebo with the same
characteristics are prepared by a pharmacist. The pa-
tients and all study personnel except the investigative
pharmacist are blinded to the treatment assignment.
The details of the treatment assignments are unknown
to any of the investigators and are contained in a set of
opaque and sealed envelopes, each marked with only the
randomization number.Trial interventions
All patients are randomized at a ratio of 1:1 to the oral
melatonin or placebo group. Time zero (T0) is defined
by randomization and the study treatment and relevant
inspections are started just after. The baseline data about
the sleeping state of the patients needs to be recorded
on day 1 after enrolment, thus the intervention begins
on day 2. The melatonin group patients receive 3 mg of
melatonin orally or through a feeding tube at 9:00 pm
for four consecutive nights (from day 2 to 5) once they
have enrolled in the study. If melatonin is administered
by a nasogastric (or nasojejunal) tube, the tablet should
be crushed and mixed with 20 ml of water, followed by
another 20 ml to flush out the remnants inside the tube.
The placebo group patients will receive the placebo
orally or through a tube using identical methods and at
the same time as the patients in the melatonin group.
After randomization, given the possible powerful effect
of the high level of noise, turning on of the lights, or the
intensive routine care and procedures on patients’ sleep
in the ICU, we will offer earplugs and eye masks to the
patients and we will dim the main light at night (from
9:00 pm to 7:00 am). Meanwhile, meetings and posters
were employed to encourage staff to minimise environ-
mental, nursing and clinical disturbances, such as clus-
tering patient care activities during the nocturnal study
periods. Additionally, nurses should select time periods
to promote sleep by avoiding routine ICU care activities
(such as the daily bath), reducing ambient noise and
turning down the lights during these periods. Other
therapy and nursing projects should follow the clinical
guidelines and nursing criterion.
In particular, during the sleep evaluation and interven-
tion period (T0 time - 9:00 pm on day 6), pain, delirium
and agitation will be managed in accordance with local
guidelines. In case of clinical indication for analgesia and
sedation, which can influence the effectiveness of mela-
tonin and sleep structure, the study treatment is stopped
and the necessary related administration is started accor-
ding to the decision of the investigators. To help manage
complex cases, three flowcharts are proposed for pain,
sedation and delirium (Figures 1, 2 and 3). They stress the
importance of considering all of those factors (that is, or-
ganic and metabolic causes, noise and light, anxiety, the
presence of invasive tools and pain) that could contribute
to agitation, delirium and pain, and should be corrected
before administering any neuroactive drug. Analgesics
(particularly opiates) must be used only in case of pain (a
Verbal Numeric Rating (VNR) score >3 or a Behavioral
Pain Scale (BPS) score >6) [44]. If delirium (CAM-ICU+)
and agitation (RASS >0) appears, after correcting the
underlying causes, the non-pharmacological protocol will
be applied and potential deliriogenic therapies stopped;
only after these interventions may physicians prescribe
Figure 1 A bedside flowchart for pain management in ICU patients. 1Consider the patient not cooperative if: RASS < -2/CAM-ICU+/communication
or linguistic barriers. 2Verbal Numeric Rating (VNR) 0 = no pain, 10 =maximal conceivable pain. Ask:“Can you quantify your pain between 0 and 10?”.
Consider at rest and breakthrough pain (e.g. = coughing, tracheo-bronchial aspiration). 3Consider the evaluation as reliable if it takes into account the
subjective parameters the patients uses to evaluate their pain: cultural, religious and familial aspects, expectation for secondary benefits. 4Behavioral
Pain Scale (BPS) 0= absence of pain, 12 =maximal pain. -Facial expression: 1. Relaxed/2. Partially tightened/3. Fully tightened/ 4. Grimacing. -Upper limbs: 1. No
movement/2. Partially bent/3. Fully bent with finger flexion/4. Permanently retracted. -Compliance to ventilation: 1. Toleration movement/ 2. Coughing but
tolerating ventilation for most of the time/ 3. Fighting ventilator/4. Unable to control ventilation.
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these participants according to local guidelines. In these
cases, the patient will stop taking the study drug but re-
main in the study and the investigator will perform the
end-of-treatment assessments immediately and the end-
of-study visit 28 days later. The trial procedures are shown
in Figure 4.
End of participation in the study
Patients will leave the study when the following occurs: (a)
the patient refuses to participate in the study; (b) an exclu-
sion criterion appears during the course of the interven-
tion; (c) a severe adverse event occurs; (d) the patient’s
condition gets worse; (e) ICU discharge or death.
Data collection and management
Trained staff will record data and fill in the web-based
collection forms. At the moment of patient inclusion,
patient data on demographic characteristics and the
history of past illnesses will be collected: age, sex, height
and weight, Acute Physiology and Chronic Health Evalu-
ation II(APACHE II) score, Sequential organ failure as-
sessment(SOFA) score, Glasgow coma scale(GCS) score,
diagnosis, and comorbidities. Clinical, physiological and
analytical variables such as vital signs (temperature (T),blood pressure (BP), heart rate (HR), and respiratory rate
(RR)), routine ICU laboratory tests (white blood count
(WBC), serum creatinine (SCr), blood urea nitrogen
(BUN), alanine aminotransferase (ALT), and aspartate
aminotransferase (AST)) will be recorded at the moment
of inclusion. The duration of time of ventilation, ventila-
tion mode, the number of days in delirium, the ICU length
of stay and the names, dose, duration of use and time of
last use of sedatives, analgesics medications and vasopres-
sor drugs will also be recorded prior to study inclusion.
Furthermore, sleep-related baseline data, including ob-
jective and subjective sleep quality and anxiety levels
should be recorded. Subjective sleep quality, including
the TST, the length of sleep at night (9:00 pm to
7:00 am) and in the day (7:00 to 9:00 pm), sleep archi-
tecture (NREM stage 1 and 2, SWS and REM), sleep dis-
ruption (the number of arousals and the duration of
sleep), will be monitored for one 24-hour period using a
portable PSG device from day 1 9:00 pm to day 2 9:00 pm.
The PSG remains the gold standard for sleep quality as-
sessment. Electroencephalographs (EEG; O1/M2, C4/M1),
electromyographs (EMG), electrooculographs (EOG; right
and left) and electrocardiographs (ECG; lead II) will be re-
corded. The patients’ skin will be prepared according to
standard techniques. Gold cup EEG electrodes will be
Figure 2 A bedside flowchart for agitation management in ICU patients. 1Always aim for RASS target =0/-1 (patient awake and tranquil, well
adapted despite invasive tool and critical condition). RASS target may be between -2 to -4 if required by clinical conditions. 2Sepsis, hypo-perfusion,
hypo/hyperglycemia, hypoxia, fever, electrolyte imbalance, alkalosis/acidosis. 3Mode of ventilation; bladder catheter positioning; bronchial aspiration.
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national 10 to 20 System. Two EOG electrodes will be
used for the right and left eye movements. The EMG
electrodes will be located over the right and left masseter
(facial) muscles. The electrode application will be per-
formed by the specialist.
The subjective sleep quality refers to the subjective
feelings of the nightly sleep status of the patients. The
baseline nightly sleep perceptive quality (day 1 9:00 pm
to day 2 7:00 am) will be evaluated using the RCSQ at
9:00 am on day 2. The RCSQ contains five 100 mm vis-
ual analogue scales (VAS): sleep depth, latency, awake-
nings, time awake and quality of sleep (higher scores
indicate better sleep). The RCSQ was pilot tested in a
medical ICU and validated with overnight PSG in medical
ICU patients. In our study, patients who are unable to
write were assisted; the patients used their current com-
munication strategy to indicate where the investigator
should mark the VAS.
Anxiety is defined as a state marked by apprehension,
agitation, increased motor activity, arousal, and fearful
withdrawal. The baseline anxiety levels are assessed on
day 2 at 9:00 am via self-report using the 100 mm VAS-A,
which is presented to patients with a vertical orientationsuch as a thermometer. The bottom of the scale is the
statement ‘not anxious at all’ and the top is “most anxious
ever.” Patients indicate their current level of anxiety in re-
sponse to ‘How are you feeling today?’. The VAS-A score
is the number of millimetres from the bottom edge of the
line (not anxious at all) to the patient’s mark. The VAS-A
and the Spielberger State Anxiety Inventory are correlated
(r = 0.4916 to r = 0.8219), demonstrating concurrent
validity.
During the intervention period (days 2 to 5), outcome-
related data, such as the objective and subjective sleep
quality, and the anxiety level should be recorded. Analyses
are limited to the fourth day (day 5 at 9:00 pm to day 6 at
9:00 am) because the potential chronophypnotic benefits
of melatonin are not immediate and may take at least
three days to be realised. Therefore, objective sleep quality
should be monitored for one 24-hour period using the
PSG from day 5 at 9:00 pm to day 6 at 9:00 pm, and the
associated parameters and methods as described in the
‘Methods/Design’ section. Meanwhile, the subjective sleep
quality and anxiety levels should be evaluated at 9:00 am
on day 6 and the related methods have been previously
described. In addition, daily information including the
vital signs and lab parameters, the SOFA score,
Figure 3 A bedside flowchart for delirium management in ICU patients. 1Sepsis, hypo-perfusion, hypo/hyperglycemia, hypoxia, fever, electrolyte
imbalance, alkalosis/acidosis. 2None pharmacological protocol. Orientation: Use patient’s visual and auditory aids, Encourage communication calling the
patient by name, Availability of patient’s personal belongings, Coherence between physicians and staff intervention, Use music or TV during the
daytime. Environment: Lights off during the night, on during the daytime, Orient patients’ beds to allow vision of sunlight, Discourage sleep during
the daytime, Patient mobilization and physiotherapy during the daytime, Control excessive noise during the daytime, Avoid medical and nursing
procedures during the night. 3Consider to stop or decrease deliriogenic therapy: anticholinergic drug, metoclopramide, inhibitor of protonic pump,
promethazine, etc.
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well as the mode, parameter and duration of mechanical
ventilation should be recorded.
The sound and illuminance levels are recorded from
day 1 to day 6 using the integrated sound pressure level
meter and the illuminance level meter. Continuous
equivalent sound pressure levels (Leq) in ‘A’ weighted
decibels and peak sound pressure levels (Lpeak) in ‘C’
weighted decibels are logged every second. The illumi-
nance level (in lux) is recorded once per minute using a
sensor placed close to the patient’s head. The bedside
nurse should be asked to log an event whenever the
patient received treatment or care. The event log will
contain the following items: clinical assessment, tracheal
suctioning, pressure area care, physiotherapy, mouth or
eye care, blood test (sampling), washing, non-invasive
blood pressure, eating and drinking, dressing, pain, lineinsertion and X-ray. Drug records are compiled daily for
drugs that are known to adversely affect sleep or mela-
tonin pharmacokinetics.
At the time of the ICU discharge, patients’ data and vital
statuses, lengths of mechanical ventilation, the number of
days of antibiotics use, the number of delirium-free days,
the length of the ICU stay and ICU mortality will be
recorded.
To investigate the enteral absorption and metabolism of
orally administered melatonin in critically ill patients du-
ring their ICU stay and to evaluate the serum melatonin
levels and their circadian variations in these patients, the
melatonin levels are measured in blood samples taken on
days 1 and 2 (before the intervention) and days 5 and 6
(four days after the intervention) at 20:45 (before adminis-
tration), 9:10 pm, 9:30 pm, 00:00 am, 3:00 am, 6:00 am,
2:00 pm and 8:00 pm in 20 patients from each group. The
Figure 4 The trial procedures flow sheet. ICU, Intensive care unit; PSG, Polysomnography; RCSQ, Richards Campbell sleep questionnaire; SOFA,
Sequential organ failure assessment; VAS-A, Visual analogue scale-anxiety.
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sured at the same time points. In addition, plasma levels
of SOD, MDA, catalase (CAT), IL-6 and IL-8 are mea-
sured at 07:00 am on days 2 and 6.
Current sample size justification
Primarily, we expect an increase in the time of the pa-
tient’s night sleep after melatonin administration in ICU
patients with sleep deprivation. Based on retrospective
data from our institution in the same population (mean
TST from the nightly sleep was 3.5 hours with a SD of
1.8 hours). A 20% (0.7 hour) difference in the nightly
sleep time between the two study arms is considered
clinically relevant and likely to influence practice. Using
the Power Analysis and Sample Size for Windows soft-
ware (PASS2000, NCSS, Kaysville, Utah, United States),
we will need to study 82 experimental subjects and 82
control subjects to be able to reject the null hypothesis
that the population means of the experimental and con-
trol groups are equal with a probability (power) of 0.8 bythe two-side paired t-test. The Type I error probability
with testing this null hypothesis is 0.05. Assuming a
dropout rate of 20%, 99 patients per group will be
recruited.
Statistical analysis
All analyses will be performed according to the intention-
to-treat principle, that is, all randomized patients will be
analysed in the groups to which they were originally allo-
cated and will be blinded to treatment assignment. Base-
line patient characteristics will be compared and described
using the appropriate statistics. Categorical variables will
be presented as the numbers and percentages and will be
analyzed by the χ2- tests or Fisher’s exact tests, or when
appropriate, as relative risks. Continuous variables will be
checked for normal distribution by the Kolmogorov-
Smirnov test. Normally distributed variables will be
expressed by their mean and standard deviation; non-
normally distributed variables will be expressed by their
medians and 95% confidence levels. Comparisons of
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t-test for normally distributed variables and the Mann-
Whitney U test for non-normally distributed variables.
Appropriate (linear, logistic, or Poisson) regression will be
generated for the identification of the determinants of out-
comes and for the correction of baseline covariates.
One-way repeated measures analysis of variance
(ANOVA) were used to determine differences in the
sleep variables, the subjective sleep quality, anxiety levels
and plasma levels of melatonin, cortisol and norepine-
phrine. Twenty-eight day mortality will be analysed ac-
cording to the Kaplan-Meier method and the results will
be compared with the log-rank test hazard ratios and
reported with 95% confidence limits. The number of
delirium-free days, ventilation-free days and antibiotics-
free days will be tested by Student’s t-test for normally
distributed data and the Mann-Whitney U-test for non-
normally distributed data. The differences in adverse
events between the intervention and placebo groups are
used for safety analyses. All tests of significance will be
at the 5% significance level and two-sided. All of the data
in this trial will be assessed with SPSS Statistics version
20.0 (SPSS, Chicago, Illinois, United States). The main
analysis will be fully specified before unmasking.
Dissemination policy
According to the Standard Protocol Items: Recommen-
dations for Interventional Trials (SPIRIT) guidelines, the
authors declare that data that break the blinding will not
be presented prior to the release of the mainline results.
Breaking of the blinding will occur at the end of the
study. A clinical article will be written on the primary
(and secondary) outcomes of the study and the results
will be disseminated regardless of the magnitude or the
direction of effect. The present trial is not industry-
initiated. As such, there are no publication restrictions
imposed by sponsors.
In addition, a full study report, an anonymized partici-
pant-level dataset and the statistical code for generating
the results will be made publicly available no later than
three years after the termination of the study for sharing
purposes.
Discussion
This study is the first large sample size, prospective
double-blind, ramdomized, placebo-controlled trial po-
wered to test the hypothesis whether melatonin improve
the sleep quality in ICU patients. Previous researches
mainly had small sample size, and they did not use the
PSG, the gold standard for assessing sleep, to evaluate
sleep quality and ignored the importance of monitoring
the all-day sleep. Therefore, our study is also the first to
use 24-hour PSG as monitoring tools to evaluate the effect
of melatonin on sleep quality in ICU patient. However, theauthors acknowledge the limitation of only including pa-
tients who pass the weaning screening and are therefore
ready to be weaned from mechanical ventilation, and not
including who are administered medication for sedation
and analgesia. Therefore, the enrolled patients might be
inclined to have the longer length of ICU stay or be rela-
tive milder case. So we can not investigate most of ICU
patients who are just admitted to ICU or treated intu-
bation and mechanical ventilation.
Even so, significant differences in the safety and/or effi-
cacy endpoints will provide important evidence for im-
proving ICU patient sleep quality. A neutral result will
also provide important insight, as this would mean that
more studies are needed to evaluate the safety and efficacy
of melatonin for ICU sleep deprivation.Trial status
The study has been initiated as planned in February
2014. One interim analysis advised continuation of the
trial. The study will be completed in February 2015.Abbreviations
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